10-K: Oncocyte Corporation Reports Full Year 2024 Results; Faces Challenges Amid Strategic Shift

Oncocyte Corporation's 2024 10-K filing reveals a year of strategic realignment, marked by increased operating losses and a focus on commercializing transplant diagnostic tests.

Summary

• Oncocyte Corporation reported a net loss of $60.7 million for the year ended December 31, 2024, compared to a net loss of $27.8 million in 2023.
• The company's accumulated deficit reached $350.5 million as of December 31, 2024.
• Net revenue increased to $1.9 million in 2024 from $1.5 million in 2023, driven by Pharma Services.
• The company recognized impairment losses of $41.9 million on in-process research and development intangible assets, specifically DetermaIO and DetermaCNI.
• Research and development expenses increased to $9.8 million in 2024 from $9.3 million in 2023.
• Sales and marketing expenses rose to $3.9 million in 2024 from $2.8 million in 2023.
• General and administrative expenses decreased to $10.2 million in 2024 from $11.2 million in 2023.
• The company completed a registered direct offering and concurrent private placement in February 2025, raising approximately $29.1 million in gross proceeds.
• Oncocyte is focusing on commercializing GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO and DetermaCNI.
• The company is pursuing regulatory approvals for its kitted tests from the FDA in the U.S. and the In Vitro Diagnostic Medical Devices Regulation in the European Union.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's revenue growth and successful capital raising, the significant increase in net losses and impairment charges weigh heavily, indicating potential financial instability and challenges ahead. The strategic shift and focus on commercialization are positive, but the overall sentiment is cautiously negative.

Positives

• Net revenue increased by 25% due to growth in Pharma Services.
• The company secured Medicare reimbursement for monitoring high-risk transplant patients.
• Oncocyte completed a registered direct offering and concurrent private placement in February 2025, raising approximately $29.1 million in gross proceeds.
• The company is actively seeking regulatory approvals for its kitted transplant products to expand their clinical use.

Negatives

• Operating losses significantly increased, reaching $60.7 million in 2024.
• The company recognized substantial impairment losses of $41.9 million on its DetermaIO and DetermaCNI intangible assets.
• The company has an accumulated deficit of $350.5 million as of December 31, 2024.

Risks

• The company has incurred operating losses since inception and may not attain profitability.
• The company may need to issue additional equity or debt securities to raise capital.
• The company's revenues in the near term will depend on its ability to commercialize a small number of diagnostic tests.
• The research and development work is costly, time-consuming, and uncertain as to its results.
• Sales of diagnostic tests could be adversely impacted by physician reluctance and competing tests.
• The company may face technology transfer challenges and expenses in adding new tests to its portfolio.
• Security breaches and other disruptions could compromise information and expose the company to liability.
• The company's products are subject to the FDA's final rule ending enforcement discretion for LDTs and regulating such tests as medical devices.
• The commercial success of diagnostic tests depends on the availability and sufficiency of third-party payer coverage and reimbursement.
• The company relies on patents and trade secrets, and its financial success will depend, in part, on its ability to obtain commercially valuable patent claims, protect its intellectual property rights and operate without infringing upon the proprietary rights of others.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows for the near future as it focuses on commercializing its transplant kitted tests and deploying sales personnel toward signing new hospital research laboratory customers. The company also intends to pursue a clinical trial in conjunction with its IVD submission in 2025, supporting its transplant products.

Management Comments

• The inherent uncertainties of developing and commercializing new diagnostic tests for medical use make it impossible to predict the amount of time and expense that will be required to complete the development and commercialization of those tests.
• There is no assurance that we will be successful in developing new technology or diagnostic tests, nor that any technology or diagnostic tests that we may develop will be proven safe and effective in diagnosis of cancer in humans or will be successfully commercialized.
• We expect that our operating expenses will continue to increase if we successfully complete the development of DetermaIO and commercialize this test.

Industry Context

The diagnostics industry is highly competitive and characterized by rapid technological change. Oncocyte competes with established companies and smaller biotechnology companies, as well as academic institutions and governmental agencies. The company's organ transplant rejection monitoring tests compete with other methods of assessing graft organ health, such as performing a manual biopsy, as well as liquid biopsy tests from competitors that measure donor-derived cell-free DNA, including CareDx, Inc., Natera, Inc., Transplant Genomics, Omixon Inc. and Devyser.

Comparison to Industry Standards

• CareDx, Inc., Natera, Inc. and Transplant Genomics are key competitors in the organ transplant rejection monitoring market with established customer bases.
• The DetermaIO test competes with multiple biomarkers already in clinical use or in development for predicting response to immunotherapy, such as Programmed Death-Ligand 1 (PD-L1) expression testing and Tumor Mutational Burden (TMB).
• Data presented at the Society for Immunotherapy of Cancer suggested that DetermaIO outperformed both PD-L1 and TMB in predicting response to checkpoint inhibitors in patients with non-small lung cancer.
• In October 2024, Oncocyte announced the results of a Phase II clinical trial that demonstrated that DetermaIO was predictive of response to atezolizumab in triple negative breast cancer patients, which were published in the peer-reviewed journal, Clinical Cancer Research.

Corporate Governance

Legal Proceedings

• The Company received a letter claiming that a recent study regarding the Company's DetermaIO immuno-oncology assay for breast cancer had triggered the Company's first milestone payment obligation under the January 10, 2020 Agreement and Plan of Merger between the Company, Insight Genetics, Inc., and certain other parties.
• The Company strongly disputes the position taken in the letter, believes the arguments to be ill-founded, and intends to vigorously defend its own position.

Related Party Transactions

• Certain sales of equity securities to Broadwood Partners, L.P., AWM Investment Company, Inc., Bio-Rad Laboratories, Inc., Andrew Arno, and Ekkehard Schtz.
• Purchases of laboratory equipment and incurrence of laboratory related expenses from Bio-Rad Laboratories, Inc.
• Financing lease payments to Bio-Rad Laboratories, Inc.
• Collaboration Agreement with Bio-Rad Laboratories, Inc.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of additional equity securities.
• Employees may be affected by changes in compensation and benefits.
• Customers may benefit from the development and commercialization of new diagnostic tests.
• Suppliers may be affected by changes in purchasing patterns.
• Creditors may be affected by changes in the company's financial condition.

Next Steps

• Continue development of GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO and DetermaCNI.
• Pursue regulatory approvals for kitted tests from the FDA in the U.S. and the In Vitro Diagnostic Medical Devices Regulation in the European Union.
• Pursue a clinical trial in conjunction with IVD submission in 2025, supporting transplant products.
• Continue to manage available cash and general operating expenses.

Key Dates

Keywords

Oncocyte, diagnostic tests, GraftAssureCore, DetermaIO, transplant, oncology, reimbursement, FDA, CLIA, financial results, impairment, capital raise, research and development, commercialization